Hierarchical strategy for identifying active chemotype classes in compound databases

Chemical Biology and Drug Design

Volumn 67, Issue 6, 2006, Pages 395-408

  Medina Franco, José Luis ^a   Petit, Joachim ^a   Maggiora, Gerald M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Chemotype enrichment plots; Chemotypes; Equivalence classes; NCI AIDS database; Parent child relationships; Paths of activity

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOTYPE 063GB; CHEMOTYPE 0F703; CHEMOTYPE 2MYHR; CHEMOTYPE 42QN1; CHEMOTYPE 4DNN1; CHEMOTYPE 7MGCM; CHEMOTYPE 839UM; CHEMOTYPE 8RVJZ; CHEMOTYPE 9F30R; CHEMOTYPE 9UKMT; CHEMOTYPE AD74D; CHEMOTYPE AU0LH; CHEMOTYPE DP10D; CHEMOTYPE E79QF; CHEMOTYPE EK7D5; CHEMOTYPE MDBLZ; CHEMOTYPE NTD2T; CHEMOTYPE QCNG9; CHEMOTYPE S33CF; CHEMOTYPE TGDM5; CHEMOTYPE UDL77; CHEMOTYPE VV0YX; CHEMOTYPE W3CJP; CHEMOTYPE W89XK; CHEMOTYPE WPS7B; CHEMOTYPE ZVUPD; CHEMOTYPE ZY6GF; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG IDENTIFICATION; DRUG STRUCTURE; HIERARCHICAL STRATEGY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, ANALYTICAL; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; MODELS, MOLECULAR; SENSITIVITY AND SPECIFICITY;

EID: 33746170606     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2006.00397.x     Document Type: Article

References (32)

1. Johnson M.A., Xu Y.-J. (2001) In: Chemical Data Analysis in the Large: The Challenge of the Automation Age; Hicks M.G., editor. Proceedings of the Beilstein-Institute Workshop, May 22nd-26th, 2000, Bozen, Italy. Available at: http://www.Beilstein-institut.de/englisch/1024/veran/index.php3?bild= proceedings.
2. Xu Y.-J., Johnson M. (2002) Using molecular equivalence numbers to visually explore structural features that distinguish chemical libraries. J Chem Inf Comput Sci;42:912-926.
3. Bemis G.W., Murcko M.A. (1996) The properties of known drugs: 1. Molecular frameworks. J Med Chem;39:2887-2893.
4. Bemis G.W., Murcko M.A. (1999) The properties of known drugs: 2. Side chains. J Med Chem;42:5095-5099.
5. Xu J., Stevenson J. (2000) Drug-like index: a new approach to measure drug-like compounds and their diversity. J Chem Inf Comput Sci;40:1177-1187.
6. Schreyer S.K., Parker C.N., Maggiora G.M. (2004) Data shaving: a focused screening approach. J Chem Inf Comput Sci;44:470-479.
7. Cases M., García-Serna R., Hettne K., Weeber M., van der Lei J., Boyer S., Mestres J. (2005) Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family. Curr Top Med Chem;5:763-772.
8. Roberts G., Myatt G.J., Johnson W.P., Cross K.P., Blower P.E., Jr (2000) LeadScope: Software for exploring large sets of screening data. J Chem Inf Comput Sci;40:1302-1314 (available at: http://www.leadscope.com/).
9. NCI AIDS Antiviral Screen. Available at: http://dtp.nci.nih.gov/docs/ aids/aids_data.html
10. NCI AIDS antiviral screen. Available at: http://dtp.nci.nih.gov/docs/ aids/searches/active_compounds.html
11. Frederick/Bethesda Data and Online Services. Available at: http://cactus.nci.nih.gov/services/som_qsar/
12. Young S.S., Hawkins D.M. (2004) Using recursive partitioning analysis to evaluate compound selection methods. In: Bajorath J., editor. Methods in Molecular Biology, Vol. 275: Chemoinformatics: Concepts, Methods, and Tools for Drug Discovery. Totowa, New Jersey, USA: Humana Press;p. 317-334.
13. Xu Y.-J., Johnson M.A. (2001) Algorithm for naming molecular equivalence classes represented by labeled pseudographs. J Chem Inf Comput Sci;41:181-185.
14. Kearsley S.K., Sallamack S., Fluder E.M., Andose J.D., Mosley R.T., Sheridan R.P. (1996) Chemical similarity using physiochemical property descriptors. J Chem Inf Comput Sci;36:118-127.
15. Johnson, M.A. Pannanugget Consulting L.L.C. Available at: http://www.pannanugget.com/
16. Spotfire, Inc., Available at: http://www.spotfire.com/
17. Liu K., Feng J., Young S.S. (2005) PowerMV: a software environment for molecular viewing, descriptor generation, data analysis and hit evaluation. J Chem Inf Model;45:515-522.
18. Schneider G., Neidhart W., Giller T., Schmid G. (1999) 'Scaffold-hopping' by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed;38:2894-2896.
19. Böhm H.-J., Flohr A., Stahl M. (2004) Scaffold-hopping. Drug Discov Today Technol;1:217-224.
20. Evans B.E., Rittle K.E., Bock M.G., Dipardo R.M., Freidinger R.M., Whiter W.L., Lundell G.F. et al. (1988) Methods for drug discovery-development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem;31:2235-2246.
21. Patchett A., Nargund R.P. (2000) Privileged structures - an update. Annu Rep Med Chem;35:289-298.
22. Frederick/Bethesda Data and Online Services. Available at: http://cactus.nci.nih.gov/ncidb2/download.html
23. Pawlak Z. (1991) Rough Sets. Theoretical Aspects of Reasoning About Data. Dordrecht, the Netherlands: Kluwer Academic Publisher.
24. Walczak B., Massart D.L. (1999) Rough sets theory. Chemomet Intell Lab Syst;47:1-16.
25. Casimiro-Garcia A., Micklatcher M., Turpin J.A., Stup T.L., Watson K., Buckheit R.W., Cushman M. (1999) Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. J Med Chem;42:4861-4874.
26. Rubinek T., McMahon J.B., Hizi A. (1994) Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and chimeric enzymes of human immunodeficiency viruses types 1 and 2 by two novel non-nucleoside inhibitors. FEBS Lett;350:299-303.
27. Balzarini J., Brouwer W.G., Dao D.C., Osika E.M., De Clercq E. (1996) Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother;40:1454-1466.
28. Barnard J., Borkow G., Parniak M.A. (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry;36:7786-7792.
29. Mitsuya H., Weinhold K.J., Furman P.A., St Clair M.H., Nusinoff S., Gallo R.C., Bolognesi D. et al. (1985) 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A;82:7096-7100.
30. Kumar R., Wang L., Wiebe L.I., Knaus E.E. (1994) Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy(or azido)-5,6-dihydro-3′-azido-3′-deoxythymidine diastereomers as potential prodrugs to 3′-azido-3′-deoxythymidine (AZT). J Med Chem;37:4297-4306.
31. Tanaka H., Takashima H., Ubasawa M., Sekiya K., Inouye N., Baba M., Shigeta S. et al. (1995) Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-5-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J Med Chem;38:2860-2865.
32. Rice W.G., Turpin J.A., Schaeffer C.A., Graham L., Clanton D., Buckheit R.W. Jr, Zaharevitz D. et al. (1996) Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. J Med Chem;39:3606-3616.